 Emily Gorell
Concepts (137)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Epidermolysis Bullosa | 14 | 2024 | 69 | 3.010 |
Why?
| | Epidermolysis Bullosa Dystrophica | 13 | 2025 | 41 | 2.750 |
Why?
| | Collagen Type VII | 8 | 2025 | 27 | 1.350 |
Why?
| | Epidermolysis Bullosa, Junctional | 1 | 2026 | 9 | 0.970 |
Why?
| | Wound Healing | 7 | 2025 | 355 | 0.820 |
Why?
| | Decision Making | 1 | 2026 | 977 | 0.570 |
Why?
| | Genetic Therapy | 3 | 2019 | 316 | 0.550 |
Why?
| | Parents | 2 | 2026 | 1403 | 0.540 |
Why?
| | Palliative Care | 1 | 2026 | 1020 | 0.530 |
Why?
| | Bandages | 3 | 2024 | 41 | 0.470 |
Why?
| | Skin, Artificial | 1 | 2014 | 3 | 0.440 |
Why?
| | Skin Diseases | 1 | 2014 | 152 | 0.360 |
Why?
| | Collagen | 1 | 2014 | 457 | 0.360 |
Why?
| | Drug Approval | 1 | 2011 | 93 | 0.320 |
Why?
| | Sunburn | 1 | 2009 | 26 | 0.290 |
Why?
| | Hair Diseases | 2 | 2024 | 10 | 0.290 |
Why?
| | Acculturation | 1 | 2009 | 55 | 0.290 |
Why?
| | Skin Neoplasms | 4 | 2024 | 849 | 0.280 |
Why?
| | Sunlight | 1 | 2009 | 78 | 0.280 |
Why?
| | Mutation | 4 | 2024 | 4075 | 0.260 |
Why?
| | Attitude to Health | 1 | 2009 | 430 | 0.230 |
Why?
| | Drug Eruptions | 1 | 2025 | 28 | 0.230 |
Why?
| | Skin | 4 | 2021 | 753 | 0.230 |
Why?
| | Infant, Newborn | 4 | 2026 | 6447 | 0.220 |
Why?
| | Ectodermal Dysplasia | 1 | 2025 | 20 | 0.220 |
Why?
| | Nephrotic Syndrome | 1 | 2025 | 43 | 0.220 |
Why?
| | Esophageal Atresia | 1 | 2025 | 32 | 0.210 |
Why?
| | Pruritus | 2 | 2014 | 59 | 0.210 |
Why?
| | Humans | 34 | 2026 | 145474 | 0.210 |
Why?
| | Psoriasis | 1 | 2025 | 115 | 0.210 |
Why?
| | Nevus | 1 | 2024 | 26 | 0.200 |
Why?
| | Gene Transfer Techniques | 2 | 2016 | 187 | 0.200 |
Why?
| | Everolimus | 1 | 2024 | 112 | 0.200 |
Why?
| | Dermatology | 3 | 2024 | 130 | 0.190 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2024 | 254 | 0.190 |
Why?
| | Keratinocytes | 3 | 2022 | 249 | 0.190 |
Why?
| | Hematuria | 1 | 2022 | 11 | 0.190 |
Why?
| | Epidermolysis Bullosa Simplex | 1 | 2022 | 14 | 0.180 |
Why?
| | Genetic Association Studies | 1 | 2024 | 369 | 0.180 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2024 | 641 | 0.170 |
Why?
| | Biopsy | 2 | 2021 | 1082 | 0.160 |
Why?
| | Surveys and Questionnaires | 7 | 2022 | 6066 | 0.160 |
Why?
| | Fluorescent Antibody Technique | 1 | 2021 | 365 | 0.160 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2025 | 1217 | 0.160 |
Why?
| | Dental Caries | 1 | 2021 | 173 | 0.150 |
Why?
| | Cannabinoids | 1 | 2021 | 184 | 0.140 |
Why?
| | Child | 12 | 2025 | 22707 | 0.140 |
Why?
| | Chronic Pain | 1 | 2022 | 291 | 0.130 |
Why?
| | Adolescent | 11 | 2025 | 22529 | 0.130 |
Why?
| | Female | 15 | 2026 | 78844 | 0.120 |
Why?
| | Anxiety | 1 | 2024 | 1118 | 0.120 |
Why?
| | Young Adult | 8 | 2025 | 14218 | 0.120 |
Why?
| | Quality of Life | 5 | 2022 | 3204 | 0.120 |
Why?
| | Male | 15 | 2025 | 72842 | 0.110 |
Why?
| | Statistics, Nonparametric | 1 | 2014 | 428 | 0.100 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 848 | 0.100 |
Why?
| | Adult | 12 | 2025 | 40777 | 0.100 |
Why?
| | Patient Reported Outcome Measures | 3 | 2022 | 497 | 0.090 |
Why?
| | Treatment Outcome | 3 | 2025 | 11772 | 0.090 |
Why?
| | Severity of Illness Index | 3 | 2025 | 2930 | 0.090 |
Why?
| | Child, Preschool | 6 | 2025 | 11853 | 0.090 |
Why?
| | Caregivers | 1 | 2020 | 1073 | 0.080 |
Why?
| | Cross-Sectional Studies | 5 | 2022 | 5904 | 0.080 |
Why?
| | Drugs, Investigational | 1 | 2011 | 31 | 0.080 |
Why?
| | Patient Selection | 1 | 2015 | 738 | 0.080 |
Why?
| | Pilomatrixoma | 1 | 2010 | 3 | 0.080 |
Why?
| | Otoscopes | 1 | 2010 | 4 | 0.080 |
Why?
| | Dermoscopy | 1 | 2010 | 11 | 0.080 |
Why?
| | Drug Compounding | 1 | 2011 | 107 | 0.080 |
Why?
| | Tissue Engineering | 1 | 2014 | 439 | 0.080 |
Why?
| | Internship and Residency | 2 | 2011 | 1267 | 0.080 |
Why?
| | United States Food and Drug Administration | 1 | 2011 | 208 | 0.080 |
Why?
| | United States | 3 | 2020 | 16098 | 0.080 |
Why?
| | Genotype | 2 | 2025 | 1852 | 0.070 |
Why?
| | Tea | 1 | 2009 | 17 | 0.070 |
Why?
| | Cost of Illness | 2 | 2022 | 324 | 0.070 |
Why?
| | Personnel Selection | 1 | 2010 | 91 | 0.070 |
Why?
| | Flavonoids | 1 | 2009 | 85 | 0.070 |
Why?
| | Dermatologic Agents | 1 | 2009 | 68 | 0.070 |
Why?
| | Chronic Disease | 1 | 2014 | 1808 | 0.070 |
Why?
| | Phenols | 1 | 2009 | 106 | 0.070 |
Why?
| | Sex Distribution | 1 | 2009 | 387 | 0.070 |
Why?
| | Pain | 2 | 2024 | 789 | 0.070 |
Why?
| | California | 1 | 2009 | 471 | 0.060 |
Why?
| | Prevalence | 2 | 2014 | 2865 | 0.060 |
Why?
| | Leadership | 1 | 2010 | 401 | 0.060 |
Why?
| | Health Education | 1 | 2009 | 346 | 0.060 |
Why?
| | Clinical Trials as Topic | 1 | 2011 | 1061 | 0.060 |
Why?
| | Infant | 4 | 2025 | 10077 | 0.060 |
Why?
| | Pylorus | 1 | 2025 | 17 | 0.060 |
Why?
| | Gastric Outlet Obstruction | 1 | 2025 | 12 | 0.060 |
Why?
| | Follow-Up Studies | 1 | 2014 | 5423 | 0.060 |
Why?
| | Arthritis, Juvenile | 1 | 2025 | 60 | 0.050 |
Why?
| | Prospective Studies | 2 | 2014 | 8057 | 0.050 |
Why?
| | Genes, Recessive | 1 | 2024 | 78 | 0.050 |
Why?
| | Retrospective Studies | 4 | 2025 | 17291 | 0.050 |
Why?
| | Administration, Topical | 1 | 2024 | 153 | 0.050 |
Why?
| | Mosaicism | 1 | 2024 | 73 | 0.050 |
Why?
| | Catastrophization | 1 | 2022 | 16 | 0.050 |
Why?
| | Delphi Technique | 1 | 2024 | 332 | 0.050 |
Why?
| | Mobility Limitation | 1 | 2022 | 67 | 0.040 |
Why?
| | Consensus | 1 | 2024 | 477 | 0.040 |
Why?
| | Middle Aged | 5 | 2025 | 36215 | 0.040 |
Why?
| | Republic of Korea | 1 | 2021 | 43 | 0.040 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2019 | 78 | 0.040 |
Why?
| | Moloney murine leukemia virus | 1 | 2016 | 13 | 0.030 |
Why?
| | Phenotype | 1 | 2024 | 3155 | 0.030 |
Why?
| | Surgical Flaps | 1 | 2016 | 142 | 0.030 |
Why?
| | Skin Cream | 1 | 2014 | 11 | 0.030 |
Why?
| | Ointments | 1 | 2014 | 25 | 0.030 |
Why?
| | Oils | 1 | 2014 | 22 | 0.030 |
Why?
| | North America | 1 | 2014 | 302 | 0.030 |
Why?
| | Hospitalization | 1 | 2024 | 2460 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2016 | 1368 | 0.020 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2020 | 1149 | 0.020 |
Why?
| | Pyrimidines | 1 | 2016 | 530 | 0.020 |
Why?
| | Ethics | 1 | 2011 | 5 | 0.020 |
Why?
| | Risk Factors | 1 | 2025 | 10885 | 0.020 |
Why?
| | Ethics, Professional | 1 | 2010 | 14 | 0.020 |
Why?
| | Facial Neoplasms | 1 | 2010 | 19 | 0.020 |
Why?
| | Quality Control | 1 | 2010 | 161 | 0.020 |
Why?
| | Cohort Studies | 1 | 2020 | 6013 | 0.020 |
Why?
| | Skin Aging | 1 | 2009 | 21 | 0.020 |
Why?
| | Polyphenols | 1 | 2009 | 21 | 0.020 |
Why?
| | Animals | 1 | 2011 | 38030 | 0.020 |
Why?
| | Career Choice | 1 | 2010 | 234 | 0.020 |
Why?
| | Wounds and Injuries | 1 | 2016 | 961 | 0.020 |
Why?
| | Faculty, Medical | 1 | 2010 | 303 | 0.020 |
Why?
| | Age Factors | 1 | 2014 | 3342 | 0.020 |
Why?
| | Administration, Oral | 1 | 2009 | 866 | 0.020 |
Why?
| | Program Evaluation | 1 | 2010 | 943 | 0.010 |
Why?
| | Time Factors | 1 | 2016 | 7123 | 0.010 |
Why?
| | Anti-Inflammatory Agents | 1 | 2009 | 477 | 0.010 |
Why?
| | Antioxidants | 1 | 2009 | 550 | 0.010 |
Why?
| | Communication | 1 | 2011 | 975 | 0.010 |
Why?
| | Double-Blind Method | 1 | 2009 | 2062 | 0.010 |
Why?
| | Aged | 2 | 2014 | 26153 | 0.010 |
Why?
|
|
Gorell's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|